Alclometasone topical

Corticosteroid-responsive dermatoses, Inflammatory & Pruritic Skin Disorders

Topical/Cutaneous Corticosteroid-responsive dermatoses, Inflammatory & Pruritic Skin Disorders Adult: As 0.05% cream/oint: Apply sparingly a thin film onto the affected area 2-3 times daily, for up to 7 days. Longer duration of treatment w/ appropriate monitoring may be necessary in patients w/ resistant or chronic conditions. Do not use for >3 wk.

Topical/Cutaneous Corticosteroid-responsive dermatoses, Inflammatory & Pruritic Skin Disorders Child: >1 yr As 0.05% cream/oint: Apply sparingly a thin film onto the affected area 2-3 times daily, for up to 7 days. Longer duration of treatment w/ appropriate monitoring may be necessary in patients w/ resistant or chronic conditions. Do not use for >3 wk.

In studies where geriatric patients (65 years of age or older) have been treated with this Cream or Ointment, safety did not differ from that in younger patients; therefore, no dosage adjustment is recommended.

Broken skin, tuberculous or viral (e.g. herpes simplex, vaccinia, varicella) skin lesions, fungal (e.g. candidiasis, tinea) or bacterial (e.g. impetigo) skin infections, rosacea, acne, perioral dermatitis.

Chronic topical corticosteroid therapy may interfere with growth and development in children Pregnancy Breastfeeding Development of Kaposi's sarcoma with prolonged use reported (discontinue therapy if it occurs) Use medium to very high potency for <2 wk to reduce local and systemic side effects Use low potency for chronic therapy Adrenal suppression may occur in younger patients or patients receiving high doses for prolonged periods Avoid medium to very high potency on face, folds, groin because can increase steroid absorption Use lower potency for peds (ie, increase BSA/kg, therefore increase systemic absorption) Monitoring Parameters Monitor for hypothalamic-pituitary-adrenal (HPA) axis suppression thru ACTH stimulation test, plasma cortisol test, and urinary free cortisol test.

C Pregnancy Category: C Lactation: It is not known whether topical administration of topical corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Use with caution.

Frequency Not Defined Skin atrophy Hypopigmentation Miliaria Cushing's syndrome Dryness Striae Acneform lesions Secondary infection Irritation HPA suppression (with higher potency used >2 wk)

Alclometasone, a synthetic glucocorticoid, induces phospholipase A2 inhibitory proteins (lipocortins) and sequentially inhibits the release of arachidonic acid, thereby depressing the biosynthesis and activity of prostaglandins, leukotrienes, and other inflammatory mediators.